In October 2021, Johns Hopkins Medicine announced that the National Institute on Drug Abuse (NIDA) within the federal National Institutes of Health, had awarded a grant of $4 million to fund a study using psilocybin, a psychedelic compound, as a therapeutic agent for smoking cessation. It is the first such grant awarded by the United States government for research on psilocybin int eh context of tobacco use in 50 years. The multi-site, three-year study will be led by researchers with Johns Hopkins Medicine in collaboration with researchers with the University of Alabama at Birmingham and with New York . . .
News Report |